<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4365">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702178</url>
  </required_header>
  <id_info>
    <org_study_id>COVAC-001</org_study_id>
    <nct_id>NCT04702178</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of COVAC Vaccines in Healthy Adults</brief_title>
  <official_title>A Randomized, Observer-Blind, Dose-Escalation Phase 1/2 Clinical Trial of COVAC Vaccines in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Government of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Government of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vaccine Formulation Institute (VFI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SEPPIC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      VIDO has developed two vaccines called COVAC-1 and COVAC-2. The Phase 1 portion of the&#xD;
      COVAC-2 trial is detailed below. The study description will be updated once the COVAC-1 Phase&#xD;
      1 portion of the trial is approved.&#xD;
&#xD;
      The study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike&#xD;
      protein is the part of the virus that is responsible for attaching to the surface of host&#xD;
      cells. COVAC-2 contains a SWE adjuvant. An adjuvant is a compound that is added to a vaccine&#xD;
      to help the vaccine produce a better immune response. The SWE adjuvant belongs to a family of&#xD;
      oil-based adjuvants that have been given to millions of people around the world as part of&#xD;
      influenza vaccines. The COVAC-2 vaccine is expected to stimulate the body to make antibodies&#xD;
      against the S1 protein. The antibodies will recognize the viral spike protein if the body is&#xD;
      exposed to the virus and prevent COVID-19 illness. In animal studies, the immune response&#xD;
      generated by the COVAC-2 vaccine was able to protect the vaccinated animals against a severe&#xD;
      SARS-CoV-2 infection.&#xD;
&#xD;
      Phase 1 is a single-centred trial of the SARS-CoV-2 vaccines to be completed in Canada. It&#xD;
      will be a randomized, observer-blinded, and placebo-controlled study to assess the safety and&#xD;
      immunogenicity of three dosing levels (25, 50, and 100 µg protein) administered twice (4&#xD;
      weeks apart) in healthy adults 18 through 54 years of age (Phase 1a), 55 through 69 years of&#xD;
      age (Phase 1b), and 70 years of age and older (Phase 1c).&#xD;
&#xD;
      Enrolment and vaccination of participants will be staggered over time based on participant&#xD;
      age and vaccine dose, except for groups in Phase 1b and Phase 1c, which will be enrolled at&#xD;
      the same time. Approval will be sought from the Data Safety Monitoring Board (DSMB) to&#xD;
      proceed with the second dose in each group, to enroll at each dose level, and to enroll in&#xD;
      the older age groups for each dose level.&#xD;
&#xD;
      Within the same age group, the 8 participants receiving the lowest dose are randomized with 4&#xD;
      participants receiving placebo; the 8 participants receiving the medium dose are randomized&#xD;
      with 4 participants receiving placebo; and the 8 participants receiving the highest dose are&#xD;
      randomized with 4 participants receiving placebo.&#xD;
&#xD;
      Within each dose level of 12 participants, it is proposed to immunize a first cohort of 3&#xD;
      participants (including at least 2 active vaccine participants) and pending no holding rule&#xD;
      is met after 7 days, to immunize the remaining 9 participants within that dose level.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs) from the first injection to Day 28, in all participants, in all groups</measure>
    <time_frame>Day 0 - 28</time_frame>
    <description>The occurrence of each solicited local and general AE, during each 7-day follow-up period after injection (e.g. the day of injection and 6 subsequent days);&#xD;
The occurrence of any unsolicited AEs for the entire study period;&#xD;
The occurrence of any hematological (hemoglobin level, WBC, lymphocyte, neutrophil, eosinophil, and platelet count) and biochemical (ALT, AST, BUN, and Cr) clinically significant laboratory abnormality through to Day 28 and;&#xD;
The occurrence of any serious AEs (SAEs), medically attended events (MAE), or adverse event of special interest (AESI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of AEs from the second injection to Day 56 (28 days post injection), in all participants, in all groups</measure>
    <time_frame>Day 28 - 56</time_frame>
    <description>The occurrence of solicited local and general AE, during each 7-day follow-up period after the second injection (e.g. the day of 2nd injection and 6 subsequent days);&#xD;
The occurrence of any unsolicited AEs for the entire study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific antibody response induced by the vaccine against the SARS-CoV-2 S protein as measured by ELISA</measure>
    <time_frame>Days 0, 7, 14, 28, 35, 42, 56, 90, 120, and 365</time_frame>
    <description>The immune response to the study vaccine, as measured by antibody (e.g. IgG and other isotypes) directed to spike antigen pre-injection (Day 0) and post-injection(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific cell-mediated immunity (CMI) response induced by the vaccine against the SARS-CoV-2 virus</measure>
    <time_frame>Days 0, 7, 14, 28, 35, 42, 120, and 365</time_frame>
    <description>o The immune response to the study vaccine, as measured by cell immune response markers in PBMCs collected pre-injection (Day 0) and post-injection(s)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Specific antibody response induced by the vaccine against the SARS-CoV-2 RBD protein as measured by ELISA</measure>
    <time_frame>Days 0, 7, 14, 28, 35, 42, 56, 90, 120, and 365</time_frame>
    <description>• The immune response to the study vaccine, as measured by antibody directed to RBD antigen pre-injection (Day 0) and post-injection(s)</description>
  </other_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <arm_group>
    <arm_group_label>Group A-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 25 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 50 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 100 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 25 µg: 8 healthy adults 55 - 69 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults 55 - 69 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 50 µg: 8 healthy adults 55 - 69 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults 55 - 69 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 100 µg: 8 healthy adults 55 - 69 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults 55 - 69 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 25 µg: 8 healthy adults ≥70 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group N-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults ≥70 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group O-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 50 µg: 8 healthy adults ≥70 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults ≥70 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Q-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVAC-2 100 µg: 8 healthy adults ≥70 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group R-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control: 4 healthy adults ≥70 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVAC-2</intervention_name>
    <description>Intramuscular vaccine against SARS-CoV-2</description>
    <arm_group_label>Group A-2</arm_group_label>
    <arm_group_label>Group C-2</arm_group_label>
    <arm_group_label>Group E-2</arm_group_label>
    <arm_group_label>Group G-2</arm_group_label>
    <arm_group_label>Group I-2</arm_group_label>
    <arm_group_label>Group K-2</arm_group_label>
    <arm_group_label>Group M-2</arm_group_label>
    <arm_group_label>Group O-2</arm_group_label>
    <arm_group_label>Group Q-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Intramuscular injection of saline placebo</description>
    <arm_group_label>Group B-2</arm_group_label>
    <arm_group_label>Group D-2</arm_group_label>
    <arm_group_label>Group F-2</arm_group_label>
    <arm_group_label>Group H-2</arm_group_label>
    <arm_group_label>Group J-2</arm_group_label>
    <arm_group_label>Group L-2</arm_group_label>
    <arm_group_label>Group N-2</arm_group_label>
    <arm_group_label>Group P-2</arm_group_label>
    <arm_group_label>Group R-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for the study, each participant must satisfy all of the following criteria:&#xD;
&#xD;
          1. Male and female healthy adults ages 18 years of age or older;&#xD;
&#xD;
          2. Good general health as determined by screening evaluation no greater than 30 days&#xD;
             before immunization;&#xD;
&#xD;
          3. If female of child-bearing potential and heterosexually active, practice of adequate&#xD;
             contraception for 30 days prior to injection, negative pregnancy test on the day of&#xD;
             injection, and agreement to continue adequate contraception until 180 days after the&#xD;
             second injection and;&#xD;
&#xD;
          4. Written informed consent, after review of the consent form and having adequate&#xD;
             opportunity to discuss the study with an investigator or a qualified designee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participant with any of the following criteria will be excluded:&#xD;
&#xD;
          1. Presence of any febrile illness or any known or suspected acute illness on the day of&#xD;
             any immunization;&#xD;
&#xD;
          2. Any physical findings suggestive of acute or chronic illness;&#xD;
&#xD;
          3. Any immunodeficiency (congenital or acquired);&#xD;
&#xD;
          4. Receiving systemic immunosuppressive therapy or history of receiving chemotherapy in&#xD;
             last 5 years other than topical agents;&#xD;
&#xD;
          5. Receipt of systemic glucocorticoids (a dose ≥ 20 mg/day prednisone or equivalent for&#xD;
             14 days) within 1 month, or any other cytotoxic or immunosuppressive drug within 6&#xD;
             months;&#xD;
&#xD;
          6. Cancer diagnosis in the last 5 years, excluding basal cell and squamous cell carcinoma&#xD;
             of the skin, which are allowed;&#xD;
&#xD;
          7. Presence of autoimmune disease;&#xD;
&#xD;
          8. Receipt of any investigational drug within 6 months;&#xD;
&#xD;
          9. Receipt of any authorized vaccines within 2 weeks of study immunization;&#xD;
&#xD;
         10. Receipt of any other SARS-CoV-2/COVID-19 or other experimental coronavirus vaccine(s)&#xD;
             at any time prior to or during the study;&#xD;
&#xD;
         11. Receipt of blood products or immunoglobulin (IVIg or IMIg) within 3 months of study&#xD;
             entry/baseline serologic evaluation;&#xD;
&#xD;
         12. Current anti-tuberculosis therapy;&#xD;
&#xD;
         13. History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the study vaccine;&#xD;
&#xD;
         14. Hematologic or biochemical laboratory abnormalities (blood or urine), as defined by&#xD;
             lab normal ranges. To exclude transient abnormalities, the investigator may repeat a&#xD;
             test once, and if the repeat test is normal according to local reference ranges,&#xD;
             participant may be enrolled. Grade 1 abnormalities of laboratory values will not be&#xD;
             exclusionary if considered not clinically significant by the investigator and;&#xD;
&#xD;
         15. Known current or previous laboratory-confirmed SARS-CoV-1 OR SARS-CoV-2 infection, as&#xD;
             documented by a positive polymerase chain reaction (PCR) test from a nasal swab OR&#xD;
             known positive serology.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne M Langley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Center for Vaccinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Mutch</last_name>
    <phone>1-902-470-8141</phone>
    <email>Jill.Mutch@iwk.nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trina Racine, PhD</last_name>
    <phone>1-306-966-3328</phone>
    <email>trina.racine@usask.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology, Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne M Langley, MD</last_name>
      <phone>1-902-470-8141</phone>
      <email>joanne.langley@dal.ca</email>
    </contact>
    <investigator>
      <last_name>Joanne M Langley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott A Halperin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelly McNeil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Volker Gerdts</investigator_full_name>
    <investigator_title>Director &amp; CEO Vaccine and Infectious Disease Organization</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

